Optimal Treatments for NSCLC Patients Harboring Primary or Acquired Amplification

Optimal Treatments for NSCLC Patients Harboring Primary or Acquired Amplification

Background : In non-small cell lung cancer (NSCLC) patients harboring MET mutations, MET-tyrosine kinase inhibitors (TKIs) have been proven to achieve a good response. However, the relative efficacy of different therapeutics in primary NSCLC patients with MET amplification and the treatment options...

Full description

Bibliographic Details
Main Authors: Dantong Sun MD, Junyan Tao MD, Weihua Yan MD, Jingjuan Zhu MD, Hai Zhou MD, Yingying Sheng MD, Chaofan Xue MD, Hong Li PhD, Helei Hou MD, PhD
Format: Article
Language:English
Published: SAGE Publishing 2022-09-01
Series:Technology in Cancer Research & Treatment
Online Access:https://doi.org/10.1177/15330338221128414

Internet

https://doi.org/10.1177/15330338221128414

Similar Items